Effect of a single psilocybin treatment on Fos protein expression in male rat brain.

5-HT2A c-fos central amygdala neurons oligodendrocytes psychedelic

Journal

Neuroscience
ISSN: 1873-7544
Titre abrégé: Neuroscience
Pays: United States
ID NLM: 7605074

Informations de publication

Date de publication:
04 Jan 2024
Historique:
received: 17 09 2023
revised: 31 12 2023
accepted: 02 01 2024
medline: 7 1 2024
pubmed: 7 1 2024
entrez: 6 1 2024
Statut: aheadofprint

Résumé

Psilocybin has received attention as a treatment for depression, stress disorders and drug and alcohol addiction. To help determine the mechanisms underlying its therapeutic effects, here we examined acute effects of a range of behaviourally relevant psilocybin doses (0.1-3 mg/kg SC) on regional expression of Fos, the protein product of the immediate early gene, c-fos in brain areas involved in stress, reward and motivation in male rats. We also determined the cellular phenotypes activated by psilocybin, in a co-labeling analysis with NeuN, a marker of mature neurons, or Olig1, a marker of oligodendrocytes. In adult male Sprague-Dawley rats, psilocybin increased Fos expression dose dependently in several brain regions, including the frontal cortex, nucleus accumbens, central and basolateral amygdala and locus coeruleus. These effects were most marked in the central amygdala. Double labeling experiments showed that Fos was expressed in both neurons and oligodendrocytes. These results extend previous research by determining Fos expression in multiple brain areas at a wider psilocybin dose range, and the cellular phenotypes expressing Fos. The data also highlight the amygdala, especially the central nucleus, a key brain region involved in emotional processing and learning and interconnected with other brain areas involved in stress, reward and addiction, as a potentially important locus for the therapeutic effects of psilocybin. Overall, the present findings suggest that the central amygdala may be an important site through which the initial brain activation induced by psilocybin is translated into neuroplastic changes, locally and in other regions that underlie its extended therapeutic effects.

Identifiants

pubmed: 38184069
pii: S0306-4522(24)00001-0
doi: 10.1016/j.neuroscience.2024.01.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Auteurs

Douglas Funk (D)

Campbell Family Research Institute, Centre for Addiction and Mental Health, Toronto M5S 2S1, Canada. Electronic address: douglas.funk@camh.ca.

Joseph Araujo (J)

Transpharmation Ltd., Fergus N1M 2W8, Canada; Mindset Pharma, Toronto M5V 0R2, Canada.

Malik Slassi (M)

Mindset Pharma, Toronto M5V 0R2, Canada.

James Lanthier (J)

Mindset Pharma, Toronto M5V 0R2, Canada.

Jason Atkinson (J)

Mindset Pharma, Toronto M5V 0R2, Canada.

Daniel Feng (D)

Transpharmation Ltd., Fergus N1M 2W8, Canada.

Winnie Lau (W)

Transpharmation Ltd., Fergus N1M 2W8, Canada.

Anh Lê (A)

Campbell Family Research Institute, Centre for Addiction and Mental Health, Toronto M5S 2S1, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto M5S 1A8, Canada.

Guy A Higgins (GA)

Transpharmation Ltd., Fergus N1M 2W8, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto M5S 1A8, Canada.

Classifications MeSH